Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 3, 2019, Pages

  Chen, Hengxi ^a,b   Xiao, Li ^a   Li, Jinke ^a,b   Cui, Lin ^c   Huang, Wei ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; INHIBIN B; ANTINEOPLASTIC AGENT; GONADORELIN;

ADJUVANT THERAPY; AGE DISTRIBUTION; ANTRAL FOLLICLE COUNT; ANXIETY DISORDER; ARTHRALGIA; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; DEPRESSION; DRUG SAFETY; EVIDENCE BASED MEDICINE; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; INCIDENCE; INSOMNIA; MENSTRUATION; META ANALYSIS; MOOD DISORDER; MYALGIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVULATION; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PREMENOPAUSE; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VAGINAL DRYNESS; ADOLESCENT; ADULT; AGONISTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CHILD; CONVALESCENCE; DRUG EFFECT; FEMALE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MENSTRUATION; MIDDLE AGED; OVULATION; PREGNANCY; PREGNANCY RATE; PREMENOPAUSE; PRIMARY OVARIAN INSUFFICIENCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; YOUNG ADULT;

EID: 85062504078     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008018.pub3     Document Type: Review

References (83)

1. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study. Fertility and Sterility 2009;91:694-7.
2. Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: A randomized controlled trial. Obsterics and Gynecology 2013;121(1):78-86.
3. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: The GBG 37 ZORO study. Journal of Clinical Oncology 2011; 29(17):2334-41.
4. Gilani MM, Hasanzadeh M, Ghaemmaghami F, Ramazanzadeh F. Ovarian preservation with gonadotropinreleasing hormone analog during chemotherapy. Asia- Pacific Journal of Clinical Oncology 2007;3:79-83.
5. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007;12:141-7.
6. Karimi-Zarchi M, Forat-Yazdi M, Nakhaie-Moghadam M, Miratashi-Yazdi A, Teimoori S, Dehghani-Tafti A. Evaluation of fertility preservation with GnRH agonist in breast cancer cases treated with cyclophosphamide as a chemotherapy drug. International Journal of Reproductive Biomedicine. 2017; Vol. 4:Supplement 1.
7. Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR, Nakhaie-Moghadam M, Miratashi-Yazdi A, Teimoori S, et al. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. European Journal of Gynaecological Oncology 2014;35(1): 59-61.
8. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapyinduced early menopause in premenopausal women with breast cancer: A randomized trial. Journal of the American Medical Association 2011;306(3):269-76.
9. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: A randomized clinical trial. Journal of the American Medical Association 2015;314(24):2632-40.
10. Leonard RC, Adamson DJ, Bertelli G, Mansi J, Yellowlees A, Dunlop J, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: The Anglo Celtic Group OPTION trial. Annals of Oncology 2017;28:1811-6.
11. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breastcancer adjuvant chemotherapy. New England Journal of Medicine 2015;372(10):923-32.
12. Munster PN, Moore AP, Ismailkhan R, Cox CE, LacevicM, Gross-King M, et al. Randomized trial using gonadotropinreleasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapyfor breast cancer. Journal of Clinical Oncology 2012;30(5): 533-8.
13. Song G, Gao H, Yuan Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicinbased chemotherapy in premenopausal patients with breast cancer: Results from a phase II randomized trial. Medical Oncology (Northwood, London, England) 2013;30(3):667.
14. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemotherapy and Pharmacology 1987;19:159-62.
15. Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hurny C, Gelber RD, Forbes JF, et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: The impact on amenorrhea, hot flashes, and quality of life in premenopausal patients- the International Breast Cancer Study Group trial VIII. Journal of Clinical Oncology 2007; 25:263-70.
16. Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: Final long-term report of a prospective randomized trial. Journal of Clinical Oncology 2016;34(22): 2568-74.
17. Mina R, Reiff A, Silva CA, Fernandez PV, Higgins GC, Imundo LF, et al. Phase 2 trial on triptorelin for ovary protection in childhood-onset systemic lupus erythematosus. ACR/ARHP Annual Meeting. 2013.
18. Regan MM, Walley BA, Francis PA, Fleming GF, Láng I, Gómez HL, et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFT. Annals of Oncology 2017;28:2225-32.
19. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: Results from a randomized trial. Breast Cancer Research and Treatment 2009;117(3):561-7.
20. Zhang Y, Ji Y, Li J, Lei L, Wu S, Zuo W, et al. Sequential versus simultaneous use of chemotherapy and gonadotropinreleasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: Effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Research and Treatment 2018;168(3):1-8.
21. Anderson R, Yellowlees A, Dunlop J, Thomas G, Leonard R. Administration of a GnRH agonist during chemotherapy for breast cancer reduces ovarian toxicity in women aged under 40 years. Human Reproduction (Oxford, England). 2016; Vol. 31:suppl 1.1.
22. Behringer K, Wildt L, Haverkamp H, Diehl V, Pfistner B, Engert A. Results of the randomised phase II for the reduction of ovarian failure with use GnRH-analogues and oral contraceptives in young women (18-40 years) treated with intensive chemotherapy for advanced-stage Hodgkin lymphoma (HL). Haematologia. 2007; Vol. 92 Suppl 5: 63-4.
23. Ismail-Khan R, Minton S, Cox C, Sims I, Lacevic M, Gross-King M, et al. Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy. Journal of Clinical Oncology: ASCO annual meeting proceedings. 2008; Vol. 26:12.
24. Karimi-Zarchi M, Forat-Yazdi M, Nakhaie-Moghadam M. Ovarian function preservation by GnRH agonists during chemotherapy in Hodgkin lymphoma patients- A double blind randomized control trial clinical. International Journal of Gynecological Cancer. 2011; Vol. 21:Suppl 3.
25. Rossi G, Iadarola R, Lambertini M, Poggio F, Levaggi A, Bighin C, et al. The value of hormone serum concentration to predict the gonadotoxic effect of chemotherapy and the efficacy of LHRH analogs as a strategy to reduce treatmentrelated premature ovarian failure in breast cancer. Annals of Oncology. 2015; Vol. 26 Supp 6:vi3-vi25.
26. Manger K, Wildt L, Kalden JR, Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: The PREGO-Study. Autoimmunity Reviews 2006;5:269-72.
27. NCT00090844. Triptorelin for preserving ovarian function in premenopausal women receiving chemotherapy for early-stage breast cancer. www.clinicaltrials.gov/ct2/show/NCT00090844?term=chemotherapy&recrs=abdefghm&type=Intr&intr=GnRH&gndr=Female&rank=6.
28. NCT00380406. Protecting ovaries and fertility during chemotherapy - the proof trial: A randomized controlled trial of gonadotropin releasing hormone agonist (GnRHa) for fertility preservation in oncology patients. www.clinicaltrials.gov/ct2/show/NCT00380406?term=chemotherapy&recrs=abdefghm&type=Intr&intr=GnRH&gndr=Female&rank=12.
29. NCT02483767. Gonadotropin-releasing hormone agonist for the preservation of ovarian function during chemotherapy in premenopausal breast cancer (POF). www.clinicaltrials.gov/ct2/show/NCT02483767?term=chemotherapy&recrs=abdefghm&type=Intr&intr=GnRH&gndr=Female&rank=2.
30. NCT02856048. Co-treatment with GnRH analogs on the ovarian reserve in young women treated with alkylating agents for cancer (PRESOV) [Assessment of the effect of a co-treatment with GnRH analogs on the ovarian reserve in adolescents and young women treated with alkylating agents for cancer]. www.clinicaltrials.gov/ct2/show/NCT02856048?term=chemotherapy&recrs=abdefghm&type=Intr&intr=GnRH&gndr=Female&draw=2&rank=1.
31. NCT03444025. Prospective phase II randomized trial of evaluating the effect of adding LhRh analogue to the neoadjuvant chemotherapy treatment of triple negative breast cancer on pathologic complete response (pCR) rates [Neoadjuvant goserelin for triple negative breast cancer (NeoGONT)]. www.clinicaltrials.gov/ct2/show/NCT03444025?term=chemotherapy&recrs=abdefghm&type=Intr&intr=GnRH&gndr=Female&rank=13.
32. AGO clinical practice guidelines in oncology. www.agoonline.de/en/guidelines-mamma/april-2017 Data accessed in October 2018.
33. Ahmed Badawy. Additional data [personal communication]. Email to: Ahmed Badawy 16 September 2018.
34. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: Mechanisms and clinical impact. Future Oncology 2016;12(20):2333-44.
35. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. Journal of the Society for Gynecologic Investigation 1999;6: 229-39.
36. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist co-treatment in addition to cryopreservation of embrya, oocytes, or ovaries. The Oncologist 2007;12:1044-54.
37. Blumenfeld Z, Von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Human Reproduction Update 2008;14: 543-52.
38. D'avila AM, Biolchi V, Capp E, Corleta H. Age, antimullerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide. Journal of Ovarian Research 2015;8(1): 82.
39. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropinreleasing hormone antagonists. Fertility and Sterility 2005; 83:1333-8.
40. Dayangan Sayan C, Tulmac OB, Karaca G, Ozkan ZS, Yalcin S, Devrim T, et al. Could erythropoietin reduce the ovarian damage of cisplatin in female rats. Gynecological Endocrinology 2018;34(4):309-13.
41. De Koning CH, Popp-Snijders C, Schoemaker J, Lambalk CB. Elevated FSH concentrations in imminent ovarian failure are associated with higher FSH and LH pulse amplitude and response to GnRH. Human Reproduction 2000;15(7):1452-6.
42. Deeks JJ, Higgins JP, Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook Data accessed in October 2018.
43. Eman A. Elgindy. Additional or missing data [personal communication]. Email to: Eman A. Elgindy 15 September 2018.
44. Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Current Opinion in Obstetrics and Gynecology 2005;17:21-6.
45. Sibylle Loibl. Additional data [personal communication]. Email to: Sibylle Loibl 15 September 2018.
46. Loverro Giuseppe. Additional or missing data [personal communication]. Email to: Loverro Giuseppe 16 April 2018.
47. Guenther V, Alkatout I, Junkers W, Bauerschlag D, Maass N, von Otte S. Fertility preservation in female patients with breast cancer - A current overview. Geburtshilfe Frauenheilkd 2017;77(10):1088-94.
48. HaskyN, Uri-Belapolsky S, Goldberg K, Miller I, Grossman H, Stemmer SM, et al. Gonadotrophin-releasing hormone agonists for fertility preservation: Unraveling the enigma?. Human Reproduction 2015;30(5):1089-101.
49. Hickman LC, Llarena NC, Valentine LN, Liu X, Falcone T. Preservation of gonadal function in women undergoing chemotherapy a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists. Journal of Assisted Reproduction and Genetics 2018;35(4): 571-81.
50. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327: 557-60.
51. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343: D5928.
52. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org Data accessed in September 2018.
53. Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook Data accessed in September 2018.
54. Horicks F, Van Den Steen G, Houben S, Englert Y, Demeestere I. Folliculogenesis is not fully inhibited during GnRH analogues treatment in mice challenging their efficiency to preserve the ovarian reserve during chemotherapy in this model. PLoS One 2015;10(9): E0137164.
55. Horicks F, Van Den Steen G, Gervy C, Clarke HJ, Demeestere I. Both in vivo FSH depletion and follicular exposure to gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice. Molecular Human Reproduction 2018;24(4):221-32.
56. Huang YH, Zhao XJ, Zhang QH, Xin XY. The GnRH antagonist reduces chemotherapy-induced ovarian damage in rats by suppressing the apoptosis. Gynecologic Oncology 2009;112(2):409-14.
57. Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecologic and Obstetric Investigation 2007;63:102-6.
58. Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, et al. Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility. Science Translational Medicine 2013;5(185):185ra62.
59. Kano M, Sosulski AE, Zhang L, Saatcioglu HD, Wang D, Nagykery N, et al. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proceedings of the National Academy of Sciences of the United States of America 2017;114(9):E1688-97.
60. M. Karimi-Zarchi. Additional data [personal communication]. Email to: M. Karimi-Zarchi 8 December 2018.
61. Lucia Del Mastro. Additional data [personal communication]. Email to: Lucia DelMastro 15 September 2018.
62. Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA, Ugolini D, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies. Annals of Oncology 2015;51(12):S318-S319.
63. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, et al. Cancer and fertility preservation: International recommendations from an expert meeting. BMC Medicine 2016;14:1.
64. Robert C. F. Leonard. Additional or missing data [personal communication]. Email to: Robert C. F. Leonard 26 November 2018.
65. Levine JM, Kelvin JF, Quinn GP, Gracia CR. Infertility in reproductive-age female cancer survivors. Cancer 2015;121 (10):1532-9.
66. Li X, Kang X, Deng Q, Cai J, Wang Z. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: A controlled experimental animal study. Reproductive Biology and Endocrinology 2013; 11:16. DOI: 10.1186/1477-7827-11-16.
67. Luborsky J, Llanes B, Roussev R, Coulam C. Ovarian antibodies, FSH and inhibin B: Independent markers associated with unexplained infertility. Human Reproduction 2000;15(5):1046-51.
68. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female cancer survivors: Pathophysiology, preservation and the role of ovarian reserve testing. Human Reproduction Update 2005;11:69-89.
69. Maggi R, Cariboni AM, Marelli MM, Moretti RM, Andrè V, Marzagalli M, et al. GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Human Reproduction Update 2016;22(3):358-81.
70. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Human Reproduction 2004;19(6):1294-9.
71. Halle C.F. Moore. Additional or missing data [personal communication]. Email to: Halle C.F. Moore 21 May 2018.
72. Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary. Human Reproduction Update 2012;18(5):525-35.
73. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: A systematic review and meta-analysis. JAMA Oncology 2016; 2(1):65-73.
74. Pamela N. Munster. Additional or missing data [personal communication]. Email to: Pamela N. Munster 15 September 2018.
75. Peng P, Yang DZ, Zheng CY, Mo YQ, He YM, Zhang QX. Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats. Zhonghua Fu Chan Ke Za Zhi 2007;42:546-50.
76. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
77. Shelling AN, Burton KA, Chand AL, Van Ee CC, France JT, Farquhar CM, et al. Inhibin: A candidate gene for premature ovarian failure. Human Reproduction 2000;15 (12):2644-9.
78. Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: Double strand DNA breaks and microvascular compromise. Aging (Albany NY) 2011;3(8):782-93.
79. Guiping Song. Additional data [personal communication]. Email to: Guiping Song 15 September 2018.
80. Tan SJ, Lee LJ, Tzeng CR, Wang CW, Hsu MI, Chen CH. Targeted anti-apoptosis activity for ovarian protection against chemotherapy-induced ovarian gonadotoxicity. Reproductive Biomedicine Online 2014;29(5):612-20.
81. Trivers KF, Fink AK, Partridge AH, Oktay K, Ginsburg ES, Li C, et al. Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist 2014;19(8):814-22.
82. Chen H, Lina H. Adjuvant gonadotropin-releasing hormone analogues for chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database of Systematic Reviews 2009, Issue 4. DOI: 10.1002/14651858.CD008018.
83. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database of Systematic Reviews 2011, Issue 11. DOI: 10.1002/14651858.CD008018.pub2.